Thyrocare Shares Surge 2.21% After 82% YoY Profit Jump in Q2FY26

Mumbai, October 15: Thyrocare Technologies Limited’s share price is on the rise today, after the company reported strong financial results. As of 11:10 AM, the shares were up by 2.21%, or 27.90 points, and were trading at ₹1,292.50. Until now, the shares have traded within a range of ₹1,474 and ₹1,286. The traded volume stood at 36.52 lakh shares, with the company’s market cap at ₹6,702 crore. The shares have their 52-week high at ₹1,474 and their 52-week low at ₹658.

Thyrocare Technologies Limited is an Indian company that is engaged in providing automated diagnostic and preventive healthcare services. The company was established in 1996 and is headquartered in Mumbai, Maharashtra. The shares of the company are listed on NSE with the ticker symbol THYROCARE and on NSE with the code 539871.

82% YoY Profit Jump in Q2FY26

For the second quarter of the financial year 2026, Thyrocare reported strong financial results. The company’s revenue from operations grew by 22% year-on-year to reach ₹216.5 crore. EBITDA increased by 49% to ₹75.4 crore, and the net profit rose by 82% to ₹47.9 crore. This strong financial performance was due to improved efficiency, as the EBITDA margin rose to 35% and the net profit margin increased to 22%.

Operationally, the company was very active during the quarter, conducting 53.3 million tests and serving 5 million patients. Its network also expanded, with the number of active franchisees growing 20% to over 10,100. To further enhance its presence in the south, Thyrocare also opened a new regional lab in Vijayawada.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations